BIOGEN ($BIIB) posted quarterly earnings results for Q4 2025 on Friday, February 6th. The company reported earnings of $1.99 per share, beating estimates of $1.63 by $0.36. The company also reported revenue of $2,279,400,000, beating estimates of $2,248,017,586 by $31,382,414.
You can see Quiver Quantitative's $BIIB stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIOGEN Insider Trading Activity
BIOGEN insiders have traded $BIIB stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:
- PRIYA SINGHAL (Head of Development) has made 0 purchases and 2 sales selling 1,265 shares for an estimated $203,161.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BIOGEN Hedge Fund Activity
We have seen 452 institutional investors add shares of BIOGEN stock to their portfolio, and 387 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PACER ADVISORS, INC. removed 1,451,249 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $255,405,311
- BLACKROCK, INC. added 1,208,486 shares (+8.9%) to their portfolio in Q3 2025, for an estimated $169,284,718
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,135,207 shares (+65.1%) to their portfolio in Q3 2025, for an estimated $159,019,796
- D. E. SHAW & CO., INC. removed 888,283 shares (-65.0%) from their portfolio in Q3 2025, for an estimated $124,430,682
- PRIMECAP MANAGEMENT CO/CA/ removed 847,425 shares (-5.4%) from their portfolio in Q3 2025, for an estimated $118,707,294
- MARSHALL WACE, LLP added 721,706 shares (+434.9%) to their portfolio in Q3 2025, for an estimated $101,096,576
- QUBE RESEARCH & TECHNOLOGIES LTD removed 621,702 shares (-83.6%) from their portfolio in Q3 2025, for an estimated $87,088,016
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIOGEN Analyst Ratings
Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 4 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 01/30/2026
- HSBC issued a "Reduce" rating on 12/10/2025
- Stifel issued a "Buy" rating on 11/06/2025
- RBC Capital issued a "Outperform" rating on 10/31/2025
- Jefferies issued a "Buy" rating on 09/25/2025
To track analyst ratings and price targets for BIOGEN, check out Quiver Quantitative's $BIIB forecast page.
BIOGEN Price Targets
Multiple analysts have issued price targets for $BIIB recently. We have seen 12 analysts offer price targets for $BIIB in the last 6 months, with a median target of $187.5.
Here are some recent targets:
- Jay Olson from Oppenheimer set a target price of $225.0 on 01/30/2026
- Geoff Meacham from Citigroup set a target price of $185.0 on 01/27/2026
- Srikripa Devarakonda from Truist Securities set a target price of $190.0 on 01/08/2026
- Michael Yee from UBS set a target price of $185.0 on 01/07/2026
- Matthew Harrison from Morgan Stanley set a target price of $156.0 on 12/12/2025
- Mohit Bansal from Wells Fargo set a target price of $190.0 on 12/10/2025
- Rajesh Kumar from HSBC set a target price of $143.0 on 12/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
